Companies Cryptocurrencies
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc
Exchange: Nasdaq Global Select
IPO Date: 23/05/1996
CEO: Dr. Kevin Gorman
Biotechnology Healthcare 🔗
  • NBIX
  • 98.1
  • 9376074752
    market cap
  • -1.1500015
If you bought

shares of Neurocrine Biosciences Inc (NBIX) on
You would have made
Old Price $12 Current Price $12

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. The company is headquartered in San Diego, California and currently employs 585 full-time employees. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

Address: 12780 El Camino Real San Diego CALIFORNIA 92130

Stay updated.